Trial Profile
Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms Probone-II
- Sponsors Novartis
- 27 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Mar 2011 New trial record